Are there any safer options than acyclovir for immunocompromised patients?

How does acyclovir compare to other antivirals in immunocompromised patients?

Acyclovir remains a standard treatment for herpes simplex virus and varicella-zoster virus infections in immunocompromised patients, but it requires frequent dosing and intravenous administration in serious cases. Alternatives such as valacyclovir and famciclovir offer improved oral bioavailability, allowing daily administration without compromising efficacy.

Why do some patients experience treatment failure with acyclovir?

Resistance to acyclovir develops through mutations in the viral thymidine kinase gene, which prevents the drug from being phosphorylated into its active form. Resistance rates are higher among immunocompromised patients, who can carry viral strains up to 5-10% of cases.

What alternatives exist if acyclovir resistance develops?

When resistance emerges, drugs such as foscarnet and cidofovir become options. They bypass the thymidine kinase requirement and act directly on the viral polymerase. Foscarnet requires intravenous administration and frequent blood monitoring for nephrotoxicity and electrolyte imbalance.

Can foscarnet and cidofovir be used as first-line options?

Foscarnet and cidofovir are not first-line because of their toxicity profiles. They typically serve as salvage therapy after acyclovir fails. Clinical guidelines still recommend acyclovir or its prodrugs as initial treatment even in immunocompromised patients.

What happens when patients receive acyclovir for lang periods?

Extended exposure to acyclovir in the immunocompromised leads to higher risk of resistance emergence. Prolonged courses also raise the risk of crystal nephropathy, especially when hydration is inadequate.

How are newer agents addressing acyclovir limitations?

Newer antivirals such as pritelivir and amenamevir target the viral helicase-primase complex, bypassing acyclovir's mechanism. Pritelivir shows activity against acyclovir-resistant strains and has clinical trials ongoing for immunocompromised patients.